Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 293

Results For "AP"

7968 News Found

AbbVie's Rinvoq beats Humira in key arthritis trial
Clinical Trials | October 22, 2025

AbbVie's Rinvoq beats Humira in key arthritis trial

The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor


Roquette opens health and pharma solutions innovation center in Brazil
R&D | October 20, 2025

Roquette opens health and pharma solutions innovation center in Brazil

This new facility strengthens Latin America as a collaborative hub


Strides partners with Incepta to expand women's health access with WHO-prequalified contraceptive
Healthcare | October 18, 2025

Strides partners with Incepta to expand women's health access with WHO-prequalified contraceptive

Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training


Indegene strengthens consulting practice to accelerate life sciences transformation
News | October 18, 2025

Indegene strengthens consulting practice to accelerate life sciences transformation

Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability


IKS Health announces generative AI platform built on Google cloud
Digitisation | October 18, 2025

IKS Health announces generative AI platform built on Google cloud

IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow


Novelix signs technology transfer agreement with Germany-based GMBU for production of Astaxanthin
News | October 18, 2025

Novelix signs technology transfer agreement with Germany-based GMBU for production of Astaxanthin

Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program


Novo Nordisk acquires Omeros’ MASP-3 inhibitor Zaltenibart for up to US$ 340 million
News | October 17, 2025

Novo Nordisk acquires Omeros’ MASP-3 inhibitor Zaltenibart for up to US$ 340 million

Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio


Pfizer’s TUKYSA boosts front-line outcomes, extending progression-free survival in HER2+ metastatic breast cancer
Clinical Trials | October 17, 2025

Pfizer’s TUKYSA boosts front-line outcomes, extending progression-free survival in HER2+ metastatic breast cancer

Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents